Development and Characterization of 4A7: A High-Affinity Monoclonal Antibody Targeting Claudin18.2
4A7 shows great promise as a next-generation therapeutic for Claudin18.2-positive cancers, offering improved efficacy and reduced immunogenicity. This study not only highlights 4A7's potential to address unmet clinical needs but also provides a foundation for future innovations in monoclonal antibody-based cancer therapy.
Authors
- Juan Tian (ORCID: https://orcid.org/0000-0003-1496-3425)
- Yangyihua Zhou (ORCID: https://orcid.org/0000-0002-9247-7281)
- Yahui Wu
- Ran Zhang (ORCID: https://orcid.org/0000-0003-3661-7785)
- Longlong Luo (ORCID: https://orcid.org/0000-0002-8307-6478)
- Xiang Gao
Institutions
- Hunan Normal University (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/itt.s494696
- Citations
- 3
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.53